Lead program

In glioblastoma, Mesenkia aims to form partnerships to develop bispecific therapeutic drugs, together with companies in possession of promising technology to actively cross the blood brain barrier. Building a bispecific drug with KITAIbodies^® coupled with active BBB transportation will, for the first time, enable targeted therapy in glioblastoma. This biological drug candidate will have clear potential for integration into both first line therapy and standard of care (SoC) for patients with glioblastoma.

Our lead candidate is targeted to enter first-in-human studies (FIH) in 2030, with a regulatory pathway aiming for accelerated approval and potential market access in 2035.

The Mesenkia KITAIbodies^® have the potential to be an essential building block in a range of next generation biological drugs in several different solid tumor indications. The versatile properties of the KITAIbodies^® enable us to tailor the design of the drug to the specific needs for each cancer indication, depending on tumor type, target distribution and molecular sensitivity of the specific tumor to target.